Gilead Sciences, Inc. $GILD Stake Lessened by Manning & Napier Advisors LLC

Manning & Napier Advisors LLC cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.2% during the 1st quarter, HoldingsChannel reports. The fund owned 103,065 shares of the biopharmaceutical company’s stock after selling 5,606 shares during the period. Manning & Napier Advisors LLC’s holdings in Gilead Sciences were worth $14,364,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in GILD. Costello Asset Management INC grew its stake in Gilead Sciences by 70.6% in the first quarter. Costello Asset Management INC now owns 725 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 300 shares in the last quarter. Equitable Trust Co. lifted its holdings in Gilead Sciences by 1.4% during the 1st quarter. Equitable Trust Co. now owns 50,177 shares of the biopharmaceutical company’s stock worth $6,993,000 after buying an additional 714 shares during the last quarter. Whipplewood Advisors LLC grew its position in shares of Gilead Sciences by 4,700.0% in the 1st quarter. Whipplewood Advisors LLC now owns 288 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 282 shares in the last quarter. Texas Bank & Trust Co bought a new stake in shares of Gilead Sciences in the 1st quarter valued at approximately $211,000. Finally, Meadow Creek Wealth Advisors LLC raised its position in shares of Gilead Sciences by 27.3% during the 1st quarter. Meadow Creek Wealth Advisors LLC now owns 2,813 shares of the biopharmaceutical company’s stock valued at $392,000 after acquiring an additional 603 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the sale, the chief financial officer directly owned 171,646 shares in the company, valued at $21,524,408.40. This trade represents a 1.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, June 15th. The shares were sold at an average price of $123.92, for a total value of $371,760.00. Following the sale, the insider directly owned 124,234 shares in the company, valued at $15,395,077.28. The trade was a 2.36% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 83,000 shares of company stock valued at $10,824,500. Insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock traded down $5.01 during trading on Friday, hitting $129.83. 5,934,235 shares of the stock were exchanged, compared to its average volume of 7,886,756. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. Gilead Sciences, Inc. has a 12 month low of $107.75 and a 12 month high of $157.29. The stock’s fifty day moving average is $129.78 and its 200 day moving average is $134.96. The stock has a market cap of $161.19 billion, a PE ratio of 17.69 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.12. The firm had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. Gilead Sciences’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period last year, the firm posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.8 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend was Monday, June 15th. Gilead Sciences’s payout ratio is 44.69%.

Analyst Ratings Changes

Several brokerages recently issued reports on GILD. Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a research note on Wednesday, May 20th. Citigroup lifted their price target on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a report on Monday, April 13th. Leerink Partners dropped their price objective on shares of Gilead Sciences from $148.00 to $146.00 in a research note on Friday, May 8th. HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their target price for the stock from $133.00 to $155.00 in a report on Monday, July 6th. Finally, Daiwa Securities Group lowered their target price on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, May 19th. Twenty-six analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $159.04.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.